Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - olanzapine, quantity: 7.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; crospovidone; magnesium stearate; hyprolose; titanium dioxide; hypromellose; macrogol 400 - treatment of schizophrenia and related psychoses. short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder. preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - olanzapine, quantity: 5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; crospovidone; magnesium stearate; hyprolose; titanium dioxide; hypromellose; macrogol 400 - treatment of schizophrenia and related psychoses. short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder. preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - olanzapine, quantity: 2.5 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; hyprolose; crospovidone; magnesium stearate; titanium dioxide; hypromellose; macrogol 4000; sodium citrate dihydrate - treatment of schizophrenia and related psychoses. short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder. preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - citalopram hydrobromide, quantity: 12.49 mg (equivalent: citalopram, qty 10 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; lactose monohydrate; magnesium stearate; microcrystalline cellulose; maize starch; copovidone; titanium dioxide; hypromellose; macrogol 400 - treatment of major depression

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - citalopram hydrobromide, quantity: 24.98 mg (equivalent: citalopram, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium stearate; croscarmellose sodium; maize starch; copovidone; microcrystalline cellulose; lactose monohydrate; titanium dioxide; hypromellose; macrogol 400 - for treatment of major depression

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - citalopram hydrobromide, quantity: 49.96 mg (equivalent: citalopram, qty 40 mg) - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; maize starch; lactose monohydrate; croscarmellose sodium; copovidone; titanium dioxide; hypromellose; macrogol 400 - treatment of major depression

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - citalopram hydrobromide, quantity: 12.49 mg (equivalent: citalopram, qty 10 mg) - tablet, film coated - excipient ingredients: maize starch; lactose monohydrate; copovidone; microcrystalline cellulose; magnesium stearate; croscarmellose sodium; titanium dioxide; hypromellose; macrogol 400 - treatment of major depression

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - cyproterone acetate, quantity: 50 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; povidone; magnesium stearate - women: moderately severe to severe signs of androgenisation. moderately severe/severe forms of hirsutism; moderately severe/severe androgen dependent loss of scalp hair (moderately severe/severe androgenic alopecia); moderately severe/severe forms of acne and/or seborrhoea associated with other features of androgenisation. cyproterone sandoz 50mg inhibits the influence of male sex hormones which are also produced by the female. it is thus possible to treat diseases in women caused by either increased production of androgens or a particular sensitivity to these hormones. hirsutism and alopecia may be expected to recur over a period of time after cessation of treatment. if cyproterone sandoz 50mg is taken during pregnancy, the properties of the preparation may lead to signs of feminisation in the male foetus. therefore, in women of childbearing potential, pregnancy must be excluded at the commencement of treatment and ethinyloestradiol taken as well to ensure contraception. this also promotes regular menstruation. men: reduction to drive in sexual deviations. cyproterone sandoz 50mg reduces the force of the sexual urge in men with sexual deviations. whilst under treatment the man can control himself better in a predisposing stimulatory situation, but there is no influence on any deviating direction of sexual drive. abnormal patterns of sexual behaviour require treatment when they are distressing to the patient. a prerequisite for therapy is the desire by the patient for treatment. cyproterone sandoz 50mg should be supplemented by psychotherapeutic and sociotherapeutic measures in order to exploit the period to reduced drive for personal and social reorientation. inoperable prostatic carcinoma. to suppress flare with initial luteinising hormone releasing hormone (lhrh) analogue therapy; in long-term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred; in the treatment of hot flushes in patients treated with lhrh analogues or who have had orchidectomy.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - olanzapine, quantity: 10 mg - tablet, uncoated - excipient ingredients: magnesium stearate; hyprolose; lactose monohydrate; crospovidone - olanzapine is indicated for the treatment of schizophrenia and related psychoses. ,olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - olanzapine, quantity: 7.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; hyprolose - olanzapine is indicated for the treatment of schizophrenia and related psychoses. ,olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.